Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells

被引:62
作者
Bennett, Michael S.
Ng, Hwee L.
Dagarag, Mirabelle
Ali, Ayub
Yang, Otto O.
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA
关键词
D O I
10.1128/JVI.02362-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Cytotoxic T lymphocytes (CTLs) are crucial for immune control of viral infections. "Functional avidity," defined by the sensitizing dose of exogenously added epitope yielding half-maximal CTL triggering against uninfected target cells (SD50), has been utilized extensively as a measure of antiviral efficiency. However, CTLs recognize infected cells via endogenously produced epitopes, and the relationship of SD50 to antiviral activity has never been directly revealed. We elucidate this relationship by comparing CTL killing of cells infected with panels of epitope-variant viruses to the corresponding SD50 for the variant epitopes. This reveals a steeply sigmoid relationship between avidity and infected cell killing, with avidity thresholds (defined as the SD50 required for CTL to achieve 50% efficiency of infected cell killing [KE50]), below which infected cell killing rapidly drops to none and above which killing efficiency rapidly plateaus. Three CTL clones recognizing the same viral epitope show the same KE50 despite differential recognition of individual epitope variants, while CTLs recognizing another epitope show a 10-fold-higher KE50, demonstrating epitope dependence of KE50. Finally, the ability of CTLs to suppress viral replication depends on the same threshold KE50. Thus, defining KE50 values is required to interpret the significance of functional avidity measurements and predict CTL efficacy against virus-infected cells in pathogenesis and vaccine studies.
引用
收藏
页码:4973 / 4980
页数:8
相关论文
共 24 条
[1]   Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy [J].
AlexanderMiller, MA ;
Leggatt, GR ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) :4102-4107
[2]   Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes [J].
Ali, A ;
Lubong, R ;
Ng, H ;
Brooks, DG ;
Zack, JA ;
Yang, OO .
JOURNAL OF VIROLOGY, 2004, 78 (02) :561-567
[3]   Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses [J].
Ali, A ;
Jamieson, BD ;
Yang, OO .
JOURNAL OF VIROLOGICAL METHODS, 2003, 110 (02) :137-142
[4]   Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians [J].
Betts, MR ;
Krowka, J ;
Santamaria, C ;
Balsamo, K ;
Gao, F ;
Mulundu, G ;
Luo, CW ;
NGandu, N ;
Sheppard, H ;
Hahn, BH ;
Allen, S ;
Frelinger, JA .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8908-8911
[5]  
Borroto R J, 1997, Rev Panam Salud Publica, V1, P3
[6]   Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection [J].
Brander, C ;
Hartman, KE ;
Trocha, AK ;
Jones, NG ;
Johnson, RP ;
Korber, B ;
Wentworth, P ;
Buchbinder, SP ;
Wolinsky, S ;
Walker, BD ;
Kalams, SA .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (11) :2559-2566
[7]   Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development [J].
Cao, HY ;
Kanki, P ;
Sankale, JL ;
DiengSarr, A ;
Mazzara, GP ;
Kalams, SA ;
Korber, B ;
Mboup, S ;
Walker, BD .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8615-8623
[8]   Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1 [J].
Cohen, WM ;
Bianco, A ;
Connan, F ;
Camoin, L ;
Dalod, M ;
Lauvau, G ;
Ferriès, E ;
Culmann-Penciolelli, B ;
van Endert, PM ;
Briand, JP ;
Choppin, J ;
Guillet, JG .
JOURNAL OF VIROLOGY, 2002, 76 (20) :10219-10225
[9]   High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL [J].
Derby, MA ;
Alexander-Miller, MA ;
Tse, R ;
Berzofsky, JA .
JOURNAL OF IMMUNOLOGY, 2001, 166 (03) :1690-1697
[10]   Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients [J].
Fukada, K ;
Tomiyama, H ;
Wasi, C ;
Matsuda, T ;
Kusagawa, S ;
Sato, H ;
Oka, S ;
Takebe, Y ;
Takiguchi, M .
AIDS, 2002, 16 (05) :701-711